Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Perry M Elliott

Showing results (231-240 of 292) with videos related to

Pageof 30
Sort By:
European Journal of Preventive Cardiology|September 7, 2022
Indications and utility of cardiac genetic testing in athletesSilvia Castelletti, Belinda Gray, Cristina Basso, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 9, 2020
Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy RegistryJuan R Gimeno, Perry M Elliott, Luigi Tavazzi, et al.
European Journal of Medical Genetics|October 9, 2020
The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individualsJoel Salazar-Mendiguchía, Roberto Barriales-Villa, Luis R Lopes, et al.
Circulation. Cardiovascular Imaging|September 18, 2014
Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathyGabriella Captur, Luis R Lopes, Timothy J Mohun, et al.
Journal of the American College of Cardiology|August 27, 2025
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM TrialMilind Y Desai, Yuichiro Okushi, Shada Jadam, et al.
JACC. Clinical Electrophysiology|October 25, 2024
Impact of Catheter Ablation on Atrial Fibrillation Burden and Symptoms in Patients With Hypertrophic CardiomyopathyNikhil Ahluwalia, Shohreh Honarbakhsh, Rangeena Assadi, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 9, 2022
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registryLuis R Lopes, Maria-Angela Losi, Nabeel Sheikh, et al.
Heart (British Cardiac Society)|October 28, 2018
Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysisConstantinos O'Mahony, Mohammed Majid Akhtar, Zacharias Anastasiou, et al.
The New England Journal of Medicine|August 28, 2018
Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyMathew S Maurer, Jeffrey H Schwartz, Balarama Gundapaneni, et al.
European Heart Journal|January 22, 2016
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseasesYigal M Pinto, Perry M Elliott, Eloisa Arbustini, et al.
Pageof 30

Showing results (231-240 of 292) with videos related to

Sort By:
Pageof 30
European Journal of Preventive Cardiology|September 7, 2022
Indications and utility of cardiac genetic testing in athletesSilvia Castelletti, Belinda Gray, Cristina Basso, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 9, 2020
Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy RegistryJuan R Gimeno, Perry M Elliott, Luigi Tavazzi, et al.
European Journal of Medical Genetics|October 9, 2020
The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individualsJoel Salazar-Mendiguchía, Roberto Barriales-Villa, Luis R Lopes, et al.
Circulation. Cardiovascular Imaging|September 18, 2014
Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathyGabriella Captur, Luis R Lopes, Timothy J Mohun, et al.
Journal of the American College of Cardiology|August 27, 2025
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM TrialMilind Y Desai, Yuichiro Okushi, Shada Jadam, et al.
JACC. Clinical Electrophysiology|October 25, 2024
Impact of Catheter Ablation on Atrial Fibrillation Burden and Symptoms in Patients With Hypertrophic CardiomyopathyNikhil Ahluwalia, Shohreh Honarbakhsh, Rangeena Assadi, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|February 9, 2022
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registryLuis R Lopes, Maria-Angela Losi, Nabeel Sheikh, et al.
Heart (British Cardiac Society)|October 28, 2018
Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysisConstantinos O'Mahony, Mohammed Majid Akhtar, Zacharias Anastasiou, et al.
The New England Journal of Medicine|August 28, 2018
Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyMathew S Maurer, Jeffrey H Schwartz, Balarama Gundapaneni, et al.
European Heart Journal|January 22, 2016
Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseasesYigal M Pinto, Perry M Elliott, Eloisa Arbustini, et al.
Pageof 30